Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholinesterase Inhibitors | 5 | 2024 | 20 | 0.820 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 62 | 0.570 |
Why?
|
| Antipsychotic Agents | 5 | 2020 | 48 | 0.560 |
Why?
|
| Dementia | 4 | 2021 | 50 | 0.480 |
Why?
|
| Drug Prescriptions | 4 | 2019 | 25 | 0.420 |
Why?
|
| United States | 13 | 2024 | 495 | 0.390 |
Why?
|
| Medicare | 5 | 2024 | 78 | 0.390 |
Why?
|
| Aged | 11 | 2024 | 703 | 0.360 |
Why?
|
| Male | 15 | 2024 | 2491 | 0.310 |
Why?
|
| Pneumonia | 2 | 2020 | 20 | 0.310 |
Why?
|
| Nursing Homes | 3 | 2019 | 31 | 0.310 |
Why?
|
| Retrospective Studies | 8 | 2024 | 341 | 0.300 |
Why?
|
| Parkinson Disease | 2 | 2020 | 39 | 0.300 |
Why?
|
| Humans | 18 | 2024 | 4936 | 0.290 |
Why?
|
| Female | 14 | 2024 | 2523 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 1 | 0.260 |
Why?
|
| Diphosphonates | 1 | 2007 | 2 | 0.260 |
Why?
|
| Imidazoles | 1 | 2007 | 15 | 0.260 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 20 | 0.250 |
Why?
|
| Depression | 3 | 2020 | 125 | 0.250 |
Why?
|
| Refuse Disposal | 1 | 2006 | 2 | 0.240 |
Why?
|
| Environmental Pollutants | 1 | 2006 | 7 | 0.240 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 7 | 0.240 |
Why?
|
| Environmental Exposure | 1 | 2006 | 10 | 0.240 |
Why?
|
| Delirium | 1 | 2024 | 7 | 0.220 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2024 | 12 | 0.220 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 10 | 0.220 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 262 | 0.220 |
Why?
|
| Bipolar Disorder | 2 | 2014 | 10 | 0.210 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 14 | 0.210 |
Why?
|
| Medication Adherence | 2 | 2015 | 69 | 0.200 |
Why?
|
| Cholinergic Antagonists | 3 | 2024 | 20 | 0.190 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2021 | 13 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2022 | 115 | 0.170 |
Why?
|
| Absenteeism | 1 | 2020 | 2 | 0.160 |
Why?
|
| Teaching | 1 | 2020 | 11 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 20 | 0.160 |
Why?
|
| Models, Psychological | 1 | 2020 | 31 | 0.160 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 47 | 0.160 |
Why?
|
| Students, Pharmacy | 1 | 2020 | 73 | 0.150 |
Why?
|
| Education, Pharmacy | 1 | 2020 | 73 | 0.140 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2017 | 3 | 0.130 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 4 | 0.130 |
Why?
|
| Child Psychiatry | 1 | 2017 | 6 | 0.130 |
Why?
|
| Physicians, Primary Care | 1 | 2017 | 7 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2017 | 8 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 25 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 47 | 0.130 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 10 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2015 | 18 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2015 | 8 | 0.120 |
Why?
|
| Child | 5 | 2017 | 627 | 0.100 |
Why?
|
| Adolescent | 5 | 2017 | 758 | 0.100 |
Why?
|
| Activities of Daily Living | 2 | 2010 | 46 | 0.100 |
Why?
|
| Rivastigmine | 2 | 2022 | 6 | 0.090 |
Why?
|
| Galantamine | 2 | 2022 | 6 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 26 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2011 | 13 | 0.090 |
Why?
|
| Muscarinic Antagonists | 2 | 2021 | 18 | 0.090 |
Why?
|
| Mental Disorders | 1 | 2011 | 48 | 0.090 |
Why?
|
| Homes for the Aged | 1 | 2010 | 11 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 47 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 2 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 14 | 0.070 |
Why?
|
| Medicaid | 3 | 2014 | 29 | 0.070 |
Why?
|
| Middle Aged | 2 | 2015 | 967 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2007 | 177 | 0.060 |
Why?
|
| United States Environmental Protection Agency | 1 | 2006 | 1 | 0.060 |
Why?
|
| Social Behavior | 2 | 2020 | 22 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 5 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2006 | 12 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 69 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 269 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 73 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 137 | 0.050 |
Why?
|
| Young Adult | 2 | 2020 | 787 | 0.050 |
Why?
|
| Phenylcarbamates | 1 | 2022 | 5 | 0.050 |
Why?
|
| Indans | 1 | 2022 | 7 | 0.050 |
Why?
|
| Piperidines | 1 | 2022 | 15 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 4 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 66 | 0.040 |
Why?
|
| Behavior Control | 1 | 2020 | 2 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 10 | 0.040 |
Why?
|
| Adult | 2 | 2020 | 1567 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2011 | 180 | 0.040 |
Why?
|
| Incidence | 1 | 2019 | 30 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 69 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2015 | 1 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 34 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 28 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 83 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 8 | 0.020 |
Why?
|
| Infant | 1 | 2011 | 78 | 0.020 |
Why?
|
| Time Factors | 1 | 2011 | 163 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 30 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 14 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 24 | 0.020 |
Why?
|
| Social Class | 1 | 2010 | 20 | 0.020 |
Why?
|
| Quality of Life | 1 | 2010 | 87 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 4 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 258 | 0.020 |
Why?
|
| Prescriptions | 1 | 2009 | 19 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 76 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 167 | 0.020 |
Why?
|